| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/00007890-199801150-00016 |
| P698 | PubMed publication ID | 9448149 |
| P50 | author | Ignazio R Marino | Q57069999 |
| Marilyn M Wagener | Q106457841 | ||
| P2093 | author name string | N Singh | |
| J J Fung | |||
| T Gayowski | |||
| A O Shakil | |||
| C F Wannstedt | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatitis C | Q154869 |
| randomized controlled trial | Q1436668 | ||
| P304 | page(s) | 82-86 | |
| P577 | publication date | 1998-01-01 | |
| P1433 | published in | Transplantation | Q15730500 |
| P1476 | title | Interferon-alpha for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: a prospective, randomized, controlled trial | |
| P478 | volume | 65 |
| Q35173005 | An extended treatment protocol with pegylated interferon and ribavirin for hepatitis C recurrence after liver transplantation |
| Q39887907 | Antihepatitis C virus therapy in liver transplanted patients |
| Q24235577 | Antiviral prophylactic intervention for chronic hepatitis C virus in patients undergoing liver transplantation |
| Q24244687 | Antiviral prophylactic intervention for hepatitis C virus in patients undergoing liver transplantation |
| Q24202008 | Antiviral prophylaxis for the prevention of chronic hepatitis C virus in patients undergoing liver transplantation |
| Q43604476 | Antiviral therapy for hepatitis C |
| Q37630394 | Antiviral therapy of chronic hepatitis C in patients with advanced liver disease and after liver transplantation |
| Q47678268 | Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. |
| Q34340293 | Antiviral treatment for hepatitis C virus infection after liver transplantation |
| Q27011871 | Challenges of recurrent hepatitis C in the liver transplant patient |
| Q36307547 | Chronic hepatitis C virus infection and post-liver transplantation diabetes mellitus |
| Q43040909 | Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. |
| Q45739562 | Current Views on Hepatitis C Virus Infection |
| Q29620656 | Diagnosis, management, and treatment of hepatitis C |
| Q29619682 | Diagnosis, management, and treatment of hepatitis C: an update |
| Q34170315 | Disease recurrence following liver transplantation |
| Q36602497 | Effect of nonviral factors on hepatitis C recurrence after liver transplantation |
| Q45341299 | Fibrosing cholestatic hepatitis with hepatitis C virus treated by double filtration plasmapheresis and interferon plus ribavirin after liver transplantation |
| Q48067615 | GRG profiles: Professor Ignazio Marino. |
| Q33686173 | Hepatitis C and liver transplantation |
| Q77110599 | Hepatitis C and liver transplantation |
| Q35017777 | Hepatitis C in the liver transplant recipient: current understanding and treatment |
| Q50586320 | Interferon Alfa-2A and ribavirin therapy for hepatitis C recurrence after liver transplantation. |
| Q45423499 | Liver retransplantation for hepatitis C virus recurrence: a survey of liver transplant programs in the United States |
| Q58704499 | Liver transplantation and hepatitis C |
| Q36587253 | Living-donor liver transplantation and hepatitis C |
| Q43038718 | Long-term combination of interferon alfa-2b and ribavirin for hepatitis C recurrence in liver transplant patients |
| Q36788362 | Management of hepatitis C infection after liver transplantation |
| Q37844982 | Management of hepatitis C virus infection recurrence after liver transplantation: an overview. |
| Q38874771 | Management of post liver transplantation recurrent hepatitis C infection with directly acting antiviral drugs: a review |
| Q34298333 | Management of recurrent hepatitis C following liver transplantation |
| Q38109628 | New insights in recurrent HCV infection after liver transplantation |
| Q50577493 | Preemptive therapy with pegylated interferon alpha-2b and ribavirin after liver transplantation for hepatitis C cirrhosis. |
| Q27470002 | Production and Characterization of Monoclonal Antibodies Specific for a Conserved Epitope within Hepatitis C Virus Hypervariable Region 1 |
| Q35572080 | Prophylactic and preemptive therapies for hepatitis C virus-infected patients undergoing liver transplantation |
| Q34332565 | Recurrent disease after liver transplantation |
| Q73341064 | Recurrent hepatitis C in transplanted patients: more questions than answers |
| Q37019765 | SASLT practice guidelines: management of hepatitis C virus infection. |
| Q37810315 | Systematic review: anti-viral therapy of recurrent hepatitis C after liver transplantation |
| Q33596413 | The outcome of hepatitis C virus infection after liver transplantation--is it influenced by the type of immunosuppression? |
| Q33534432 | Transplantation |
| Q35672482 | Treatment of hepatitis C in solid organ transplantation |
| Q35572085 | Treatment of hepatitis C virus infection in the allograft |
| Q34027574 | Treatment of recurrent hepatitis C following liver transplantation |
| Q35543600 | Treatment strategies for hepatitis C: intervention prior to liver transplant, pre-emptively or after established disease |
| Q34210752 | Treatment strategies for recurrent hepatitis C after liver transplantation |
| Q34170425 | Viral hepatitis A, B, and C. |
| Q34033249 | Viral hepatitis in the liver transplant recipient |
| Q50567515 | [The prophylaxis and treatment of c virus liver disease in the liver transplantation setting. Narrative review] |
Search more.